



ORIGINAL ARTICLE

Multifunctionalization of cyanuric chloride for the stepwise synthesis of potential multimodal imaging chemical entities



Mário J.F. Calvete^{a,b}, Sara M.A. Pinto^{a,b,*}, Hugh D. Burrows^{a,b},
M. Margarida C.A. Castro^{b,c}, Carlos F.G.C. Geraldes^{b,c}, Mariette M. Pereira^{a,b,*}

^a Department of Chemistry, Faculty of Science and Technology, University of Coimbra, Coimbra, Portugal

^b Coimbra Chemistry Centre, CQC, University of Coimbra, Coimbra, Portugal

^c Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, Coimbra, Portugal

Received 21 November 2017; accepted 17 June 2018

Available online 22 June 2018

KEYWORDS

Porphyrins;
Aza-chelates;
Sulfonation;
Fluorescence;
Biomedical applications;
Cyanuric chloride

Abstract We report a synthetic strategy to combine different moieties in a single structure using cyanuric chloride (2,4,6-trichlorotriazine) as a starting platform for preparing potential bioimaging agents. This reacted with macrocycles of the porphyrin family and DOTA type metal chelators through mono-, di- and tri- substitution of its chlorine atoms by appropriate nucleophiles, controlling the stepwise by temperature, to produce a system that opens the potential for biomedical applications. Porphyrins were chosen as one of the sensing arms, based on their rich structural chemistry, and excellent photophysical properties, while DO3A was used since it can form a versatile aminopropionate functionalized metal ion chelator. All new compounds were fully characterized, both spectroscopically and photophysically.

© 2018 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Cancer is one of the leading causes of death worldwide and it is estimated that by 2030, the number of new cancer cases may increase by about 70%. It is accepted by both medical and scientific communities that new drugs for cancer therapy and more efficient imaging diagnostic methods to detect tumors at an early stage (Singh et al., 2015; Ethirajan et al., 2011; Calvete et al., 2014) will play a major role in solving the problem of cancer. Porphyrins have potential in both these areas. We can highlight, for example, the use of tetrapyrrolic macrocycles in photodynamic therapy (Singh et al., 2015; Ethirajan et al., 2011; Arnaut, 2011; Pereira

* Corresponding authors at: Department of Chemistry, Faculty of Science and Technology, University of Coimbra, Coimbra, Portugal.

E-mail addresses: smpinto@qui.uc.pt (S.M.A. Pinto), mmpereira@qui.uc.pt (M.M. Pereira).

Peer review under responsibility of King Saud University.



et al., 2006; Dabrowski et al., 2012), and their valuable properties for imaging. In this regard, the development of new contrast agents for medical imaging becomes imperative; currently the most widely used medical imaging processes at the clinical level are MRI (magnetic resonance imaging) (Calvete et al., 2017c; Calvete et al., 2014; Kueny-Stotz et al., 2012), SPECT (single photon emission tomography) (Calvete et al., 2017b; Srivatsan et al., 2015) and PET (positron emission tomography) (Rangacharyulu and Roh, 2015; Mewis and Archibald, 2010; Gambhir, 2002; Simoes et al., 2015).

Recently, promising techniques, such as FI (fluorescence imaging) (Josefsen and Boyle, 2012; Wagnieres et al., 1998; Lobo et al., 2016) and PAI (photoacoustic imaging) (Wu et al., 2014; Pan et al., 2013), have also gained considerable attention. Each of these techniques possesses unique strengths and weaknesses in terms of characteristics, such as spatial resolution, radiation penetration depth, contrast, imaging acquisition time, and equipment/running costs. The design/development of new chemical entities that can potentially act as multimodal contrast agents combining the advantages of each technique has gained much attention over last decade, and has the exciting prospect of overcoming the specific limitations of each technique, improving diagnosis and allowing, in best cases, the detection and characterization of small tumors (Dong et al., 2017; Luo et al., 2014).

As a strategy towards stepwise multi-functionalization to produce a multimodal chemical entity, we have turned our attention to cyanuric chloride (2,4,6-trichloro-[1,3,5]-triazine) as a useful platform that can be used to link imaging units through mono-, di- and tri- substitution of its chlorine atoms by appropriate nucleophiles. The stepwise substitution involved can be controlled by temperature, since the reactivity decreases with increasing number of substituents linked to the platform (Blotny, 2006; Puthiaraj et al., 2016; Luechai et al., 2012; Xiao et al., 2010). Given the excellent properties of porphyrins, including their straightforward structural modification, either by introduction of different functional groups or complexation with several metal ions (Ethirajan et al., 2011; Calvete et al., 2017c; Srivatsan et al., 2015; Josefsen and Boyle, 2012; Pinto et al., 2016; Henriques et al., 2016; Henriques et al., 2012; Simoes et al., 2012; Pinto et al., 2012), their photophysical properties (for example, high fluorescence quantum yields) (Arnaut, 2011; Marques et al., 2012), preferential uptake in tumors and low *in vivo* toxicity (Dabrowski et al., 2011), these have been chosen as one of the arms of this multimodal sensor. Another moiety is based on the versatility of chelates of the DOTA type (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DO3A-N- α -aminopropionate (Ferreira et al., 2009), a versatile bifunctional chelator that may form low toxicity, highly thermodynamically and kinetically stable Gd³⁺ complexes with optimized relaxivity to generate MRI contrast (Ferreira et al., 2013), or complexes with different metal ions for other imaging applications. Herein, we envisage a synthetic strategy to combine, in a single structure, multiple chemical entities which are potentially able as reporters for different imaging techniques. The new compounds were fully characterized by spectroscopic and photophysical methods.

2. Materials and methods

2.1. General

Commercially available reagents were from Aldrich and Fluo-rochem. All solvents were pre-dried according to standard laboratory techniques.

UV-visible absorption spectra were recorded on a Hitachi U-2010 spectrometer using quartz cells. The molar absorption coefficients were determined using DMSO and THF as solvents. Steady-state fluorescence spectra were obtained using a Horiba-Jobin-Yvon SPEX Fluorolog 3-22 instrument (0.5 nm slits). The fluorescence quantum yields (Φ_F) of the systems were measured under conditions of matched absorbance (0.01) at the excitation wavelength, and were obtained from the ratio of the integrated fluorescence bands of the sample and reference, expressed as a function of energy units, and multiplied by the fluorescence quantum yield of the reference, after correction for the difference in the refractive indexes between the sample and the reference solutions. A solution of 5,10,15,20-tetraphenylporphyrin (TPP) in toluene was used as standard (fluorescence quantum yield = 0.11) (Murov et al., 1993). ¹H NMR spectra were recorded on a 400 MHz Bruker Avance III NMR spectrometer. Proton chemical shifts are given in parts per million (ppm) relative to tetramethylsilane at δ 0.00 ppm. Mass spectra (ESI-FIA-TOF) were acquired using a Bruker model Micro-TOF (University Santiago de Compostela, Spain). Elemental analysis was obtained in a FISONs model EA 1108 analyzer (University Santiago de Compostela, Spain).

2.2. Synthesis

5-(4-Hydroxyphenyl)-10,15,20-triphenylporphyrin **1** was prepared following our previously described methodologies (Calvete et al., 2017a; Silva et al., 2014) and its properties are in agreement with literature data (Calvete et al., 2017a; Tome et al., 2005; Neves et al., 2012). Protected DO3A-N- α -aminopropionate **4** was prepared according to the literature, and its characterization is in agreement with previous reports (Ferreira et al., 2009).

2.2.1. Synthesis of compound **5**

Using optimized conditions, a mixture of cyanuric chloride (0.05 g, 0.27 mmol) and diisopropylethylamine (DIPEA) (0.3 mL, 3.6 mmol) was dissolved in 7 mL of tetrahydrofuran (THF). L-leucine methyl ester (0.05 g, 0.27 mmol) was added at -10 °C and the reaction was left for 30 min with stirring. Then, 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (0.170 g, 0.27 mmol) and DIPEA (0.3 mL, 3.6 mmol) were added, and the reaction was left to react 24 h at 30 °C. Finally, the protected DO3A-N- α -aminopropionate **4** (0.132 g, 0.27 mmol) and more DIPEA (0.3 mL, 3.6 mmol) were added and the reaction was left for 72 h at 60 °C. The control of each stage of the sequential reaction was performed using TLC. After solvent evaporation the reaction crude was purified using silica gel column chromatography, starting with CH₂Cl₂ as eluent to remove residual byproducts and CH₂Cl₂:ethanol (1:1) to obtain the pure compound. Compound **5** (R_f in CH₂Cl₂:ethanol (1:1) = 0.25) was obtained in 56% yield.

MS (ESI-FIA-TOF) m/z calcd for $[M + Li]^+$: $C_{78}H_{87}LiN_{13}O_{11}$ 1388.6808; found 1388.6732. 1H NMR (400 MHz) ($CDCl_3$), δ , ppm: 8.83–8.81 (broad signal, 8H, β -H), 8.16 (broad signal, 8H, Ar-H), 7.71–7.52 (multiplet, 11H, Ar-H), 4.30–4.12 (2 broad singlets, 6H, $-OCH_3$), 3.70–2.17 (multiplets, 32H, $-CH_2CH_3$, $-NCH_2CO_2^-$, $-NCH_2CHNH-$, $-HNCH_2$ -aminoacid, $-N(CH_2)_2N-$), 1.50–1.46 (multiplets, 12H, CH_3-CHCH_3 -aminoacid, $-CH-CH_2-CH$ -aminoacid, $-OCH_2CH_3$), 1.41–1.40 (broad signal, CH_3CHCH_3 -aminoacid). UV-vis (THF): λ_{max} , nm (log ϵ) 419 (5.43), 515 (4.26), 550 (4.15), 589 (3.66), 646 (3.62). Elemental Anal. calcd. for $C_{78}H_{87}N_{13}O_{11} \cdot 2H_2O$: C, 66.04; H, 6.47; N, 12.84; Found C, 65.86; H, 6.58; N, 12.73.

2.2.1.1. Synthesis of compound 5a. Compound (**5**) (0.070 g, 0.051 mmol) was dissolved in a mixture of ethanol (3 mL) and hydrochloric acid (6 M, 3 mL) and stirred overnight at room temperature. After the reaction was complete, the solvent was evaporated, the obtained compound was redissolved in water and the solvent evaporated several times. Then, the obtained solid was dissolved in water (10 mL), the solution was adjusted to pH 10–11 by addition of small portions of Dowex-1X2-100 OH⁻ resin and was left with stirring for 4 h at room temperature. The resin was transferred into a column, washed with water and eluted with hydrochloric acid (0.1 M). The reddish-brown fraction was collected and the solvent was removed under reduced pressure (temperature < 40 °C) to give compound **5a** (0.031 g, 0.024 mmol, 47%).

MS (ESI-TOF-INFUSION) m/z calcd for $[M + Na + H]^+$: $C_{70}H_{72}N_{13}NaO_{11}$ 1293.5372; found 1293.6942.

2.2.2. Synthesis of 5-(4-hydroxy-3-sulfonylphenyl)-10,15,20-(4-sulfonyltriphenyl)porphyrin 6

5-(4-Hydroxyphenyl)-10,15,20-triphenylporphyrin (0.200 g, 0.32 mmol) and chlorosulfonic acid (12 mL, 150 mmol) were stirred at 100 °C for 2 h. After this period, chloroform (400 mL) was added to the solution and a continuous water extraction was carried out, under constant stirring, until neutralization of the solution. The organic phase was washed with $NaHCO_3$ and dried with Na_2SO_3 . After solvent evaporation, deionized water was added (150 mL) and the mixture was left to hydrolyze under stirring, at 100 °C during 12 h. After water evaporation, the compound 5-(4-hydroxy-3-sulfonylphenyl)-10,15,20-(4-sulfonyltriphenyl)porphyrin (**6**) was obtained in 90% yield.

HRMS (ESI-FIA-TOF) m/z calcd for $[M + Na]^+$: $C_{44}H_{30}NaN_4O_{13}S_4$ 973.0584; found 973.0575. UV-vis (DMSO): λ_{max} , nm (log ϵ) 422 (4.36), 517 (3.41), 555 (3.14), 584 (2.94), 635 (1.94). 1H NMR (400 MHz) (DMSO), δ , ppm: 8.92–8.84 (m, 8H, β -H), 8.21–8.18 (m, 8H, *ortho*-Ph-H), 8.06–8.04 (m, 7H, *meta*-Ph-H). Elemental Anal. calcd. for $C_{44}H_{30}NaN_4O_{13}S_4 \cdot 3H_2O$: C, 52.58; H, 3.61; N, 5.57; S, 12.76; Found C, 52.00; H, 3.98; N, 5.22; S, 12.91.

2.2.3. Synthesis of compound 8

Using optimized conditions, cyanuric chloride (0.014 g, 0.074 mmol) and DIPEA (0.2 mL, 2.4 mmol) were dissolved in DMF. A solution of 5-(4-hydroxy-3-sulfonylphenyl)-10,15,20-(4-sulfonyltriphenyl)porphyrin (**6**) (0.145 g, 0.150 mmol) in DMF was then added and the reaction mixture was left for

12 h at 25 °C with stirring. After confirming the disappearance of the starting material, protected DO3A-N- α -aminopropionate **4** (0.078 g, 0.16 mmol) and DIPEA (0.1 mL, 1.22 mmol) were added and the reaction was left for 72 h at 60 °C. Compound **8** was obtained after precipitation and washing with acetone, in 42% yield.


MS (ESI-FIA-TOF) m/z calcd for $[M]^+$: $C_{115}H_{102}N_{16}O_{34}S_8$ 2507.4544; found 2507.4445. 1H NMR (400 MHz) (DMSO d_6), δ , ppm: 8.90–8.85 (broad signal, 16H, β -H), 8.21–8.01 (broad signal, 30H, Ar-H), 4.19–4.06 (multiplets, 10H, $-OCH_2CH_3$, $-OCH_3$, $-NCH_2CHNH-$), 3.64–2.61 (multiplets, 24H, $-NCH_2CO_2^-$, $-N(CH_2)_2N-$, $-NCH_2CHNH-$), 1.17 (broad triplet, 9H, $-OCH_2CH_3$). UV-vis (DMSO): λ_{max} , nm (log ϵ) 416 (5.06), 514 (3.91), 547 (3.79), 592 (3.29), 646 (3.07). Elemental Anal. calcd. for $C_{115}H_{102}N_{16}O_{34}S_8 \cdot 4H_2O$: C, 53.52; H, 4.30; N, 8.68; S, 9.94; Found C, 53.86; H, 4.28; N, 8.63; S, 9.92.

3. Results and discussion

3.1. Synthesis

The synthetic pathways to obtain the new multimodal chelator **5** are presented in Scheme 1. First we optimized the synthesis of non-symmetric 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (**1**), using our recently developed NaY/nitrobenzene synthetic methodology (Silva et al., 2014; Calvete et al., 2017a; Henriques et al., 2015; Henriques et al., 2014); the product was obtained in 16% yield. It should be noted that this method gave a twofold increase in yield compared with other standard one-pot procedures (Adler et al., 1964; Gonsalves et al., 1991). Then, the synthesis of the protected DO3A-N- α -aminopropionate **4** (Scheme 1b), was carried out using a methodology previously described by some of us (Ferreira et al., 2009). A Michael addition of Boc₂-Ser-OMe to cyclen was performed and, after isolation and purification, alkylation with ethyl bromoacetate was carried out to give the fully protected DO3A-N- α -aminopropionate derivative, in accordance with literature (Ferreira et al., 2009) with 75% yield. To obtain **4**, a selective deprotection of the amine group present at the aminopropionate arm was performed, using a solution of 10% trifluoroacetic acid in dichloromethane, giving **4** in 90% yield. Both compounds **1** (Calvete et al., 2017a) and **4** (Ferreira et al., 2009) were confirmed by 1H NMR and mass spectroscopy, and the obtained data are in agreement with the literature.

Next, we proceeded to the preparation of compound **5**. We started by reacting 1 equiv of commercially available L-leucine methyl ester (to induce more biocompatibility) (Dong et al., 1998; Mikhalenko et al., 2004; Haywood-Small et al., 2006; Drechsler et al., 1999) with 1 equiv of cyanuric chloride in THF at -10 °C in the presence of diisopropylethylamine (DIPEA). The reaction was monitored by TLC and, after 30 min, complete disappearance of cyanuric chloride was observed, concomitantly with the formation of the monoadduct derivative **2**. Then, without purification of **2**, 1 equiv of the previously synthesized porphyrin **1** was added, together with more DIPEA and left to react at 30 °C. Evolution of the reaction was monitored by TLC and compound **2** disappeared, being converted into **3** after 24 h. Finally, upon



Scheme 1 (A) Reaction pathway to obtain compound **5**. Reagents and conditions: (a) $-10\text{ }^{\circ}\text{C}$ to $-5\text{ }^{\circ}\text{C}$, 30 min, DIPEA, THF; (b) $30\text{ }^{\circ}\text{C}$, 24 h, DIPEA, THF; (c) $60\text{ }^{\circ}\text{C}$, 72 h, DIPEA, THF. (B) Reaction pathway to obtain compound **4**. Reagents and conditions: (a) RT, 4 h, K_2CO_3 , CH_3CN ; (b) RT, 4 h, ethylbromoacetate, K_2CO_3 , CH_3CN ; (c) RT, overnight, TFA (10%), CH_2Cl_2 .

addition of 1 equiv of **4** and more DIPEA, the reaction was left at $60\text{ }^{\circ}\text{C}$ for 72 h. Isolation and purification by silica gel column chromatography using CH_2Cl_2 to remove byproducts, followed by CH_2Cl_2 :ethanol (1:1) as eluents, gave product **5**, in 56% yield (Scheme 1).

In addition, to obtain water soluble structures, compound **5** was hydrolyzed using acid hydrolysis, with HCl 6 M in ethanol, in order to deprotect the carboxylic groups. However, to our dismay, the solubility of the supposed structure **5a** (Fig. 1) was also highly pH dependent, being only soluble in aqueous solution at $\text{pH} > 9$ (10^{-3} M), which is in agreement with the formation of anionic carboxylate salts. Due to strong aggregation, it was not possible to obtain ^1H NMR spectra of

the final compound **5a**, and the only characterization data obtained was its mass spectrum, which presented a peak at 1293.6942 for $[\text{M} + \text{Na}]^+$ (see Fig. S7 in SI).

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.arabjc.2018.06.005>.

Given the low water solubility presented by compound **5a**, we turned our attention to the synthesis of a more water-soluble system. To increase water solubility of the starting porphyrin, we have synthesized a new sulfonated porphyrin derivative, by chlorosulfonation of porphyrin **1**, following our previously described methodology (Gonsalves et al., 1996; Monteiro et al., 2008), using an excess of chlorosulfonic





Fig. 1 Structure of the deprotected compound **5a**.

acid, for 2 h at 100 °C (Scheme 2). After work-up, hydrolysis was performed by adding water and heating the suspension at 100 °C during 12 h. Upon full solubilization of the mixture in water and isolation/purification, 5-(4-hydroxy-3-sulfonylphenyl)-10,15,20-(4-sulfonyltriphenyl)porphyrin **6** was obtained in 90% yield. The degree of sulfonation was determined by analysis of the ¹H NMR and mass spectra, which corroborates the preferred reactivity pattern of substituted benzenes


(substitution in *para* position) and phenols (substitution in *ortho* position) (Cremlyn, 2002).

In our attempts to prepare a water soluble system, we experienced difficulties when attempting to modulate the cyanuric chloride first with protected aminoacid, followed by sulfonated porphyrin and finally DO3A, in a stepwise one-pot reaction. We never managed to obtain the desired compound bearing one "aminoester", a sulfonated porphyrin and DO3A. Since attempts to isolate intermediates were unsuccessful, we hypothesized that the intermediate bearing an aminoacid was not stable in presence of sulfonated porphyrin in the second step. We focused then on skipping the first step, and promoted the multifunctionalization directly with sulfonated porphyrin, followed by DO3A.

The synthetic pathway to prepare the target compound, involving the sequential nucleophilic substitution pattern, using cyanuric chloride was similar to that previously described for compound **5**, with some modifications. In this case we started by reacting 1 equiv of cyanuric chloride with 2 equiv of **6** in DMF, at 25 °C in the presence of 2.4 equiv of DIPEA (Scheme 3). After disappearance of the starting materials (12 h, checked by TLC), 2.1 equiv of **4** and 1.2 equiv of DIPEA were added, the reaction was left at 60 °C for 72 h. Evolution of the reaction was monitored by TLC and the



Scheme 2 Synthesis of water soluble sulfonated porphyrin **6**. (a) 100 °C, 2 h, HSO₃Cl; (b) 100 °C, 12 h, water.



Scheme 3 Reaction pathway to obtain compound **8**. Reagents and conditions: (a) 25 °C, 12 h, DIPEA, DMF; (b) 60 °C, 72 h, DIPEA, DMF.

disappearance of compound **7**. Isolation and purification of the product was achieved by precipitation with acetone and a product was obtained in 42% yield.

Next, tests were carried out in order to evaluate the solubility, and we observed that, even without deprotection of the ethyl groups of the DO3A counterpart, the compound **8** presents satisfactory solubility (10^{-3} M) in polar solvents, such as DMSO, DMF, ethanol, methanol and water.

3.2. UV/visible absorption and fluorescence spectral properties

The absorption spectra of structures **5** and **8** were recorded in THF and DMSO, respectively, and the typical five bands, B

and Soret, $Q_y(1-0)$, $Q_y(0-0)$, $Q_x(1-0)$ and $Q_x(0-0)$ of porphyrins can be seen in Fig. 2a–b (solid line). Molar absorption coefficients (ϵ) were determined using the Beer-Lambert law for both compounds (Table 1) and are in the typical range of ϵ for porphyrins reported in literature (Pinto et al., 2012; Martinez-Diaz et al., 2010).

In order to evaluate the potential of these structures for fluorescence imaging, their fluorescence spectra and quantum yields were also determined. As can be seen in Fig. 2a–b (dashed lines), both fluorescence spectra show two bands: at 650 nm and 719 nm for **5** and 652 nm and 717 nm for **8**. These are within the 650 – 1450 nm spectral window required for imaging, where tissue components have their lowest absorption




Fig. 2 UV-Visible and fluorescence spectra of (a) compound **5** in THF; (b) compound **8** in DMSO.

Table 1 Molar absorption coefficients, ϵ , and fluorescence quantum yields, Φ_F , of compounds 5 and 8 .						
		λ_{max} (nm), ϵ ($\text{L mol}^{-1} \text{cm}^{-1}$)				Φ_F
1 (in THF)	B(0-0)	$Q_y(1-0)$	$Q_y(1-0)$	$Q_x(1-0)$	$Q_x(0-0)$	0.06 (Pinto et al., 2012)
	417 nm	513 nm	548 nm	589 nm	650 nm	
	1.19×10^5	7.21×10^3	3.39×10^3	2.07×10^3	1.78×10^3	
5 (in THF)	B(0-0)	$Q_y(1-0)$	$Q_y(1-0)$	$Q_x(1-0)$	$Q_x(0-0)$	0.05
	419 nm	515 nm	550 nm	589 nm	646 nm	
	2.71×10^5	1.82×10^4	6.04×10^3	4.56×10^3	4.21×10^3	
6 (in DMSO)	B(0-0)	$Q_y(1-0)$	$Q_y(1-0)$	$Q_x(1-0)$	$Q_x(0-0)$	0.05
	419 nm	517 nm	551 nm	589 nm	643 nm	
	1.04×10^5	6.43×10^3	2.56×10^3	1.67×10^3	1.10×10^3	
8 (in DMSO)	B(0-0)	$Q_y(1-0)$	$Q_y(0-0)$	$Q_x(1-0)$	$Q_x(0-0)$	0.03
	416 nm	514 nm	547 nm	592 nm	646 nm	
	1.14×10^5	8.17×10^3	6.23×10^3	1.96×10^3	1.18×10^3	

(Pansare et al., 2012). Although fluorescence quantum yields in THF (for **5**) and DMSO (for **8**) are modest, they are acceptable for imaging since they fall within the important near infrared window in biological tissues, and are comparable to values found in the literature for free base porphyrins (Pinto et al., 2012; Pinto et al., 2011) (Table 1). However, we were expecting that compound **8**, possessing two porphyrin units in its structure, could have a higher fluorescence quantum yield, as we know from our previous studies (Pinto et al., 2012). Future time-resolved fluorescence measurements are proposed to obtain a deeper understanding of the photophysics of these multimodal systems with the objective of improving emission quantum yields.

4. Conclusions

In summary, we have reported the synthesis, structural characterization and spectral evaluation of two new multifunctional chemical entities, based on the triazine molecule as starting platform, for the potential development of multimodal imaging agents. These have modulated lipophilicity, and have three

arms bearing macrocycles of the porphyrin family, chelates of the DOTA type (DO3A) and, in the case of the triad molecule **5**, an aminoacid to increase biocompatibility. We have managed to overcome the limited solubility of triad **5**, by synthesizing compound **8**, which presents reasonable water solubility, even without deprotection of DO3A ethyl groups. The absorption and fluorescence spectra and quantum yields were also determined, and the preliminary findings suggest that the optical properties presented by these systems indicate that they have potential as fluorescence imaging agents and, following complexation of the DO3A ligand with Gd^{3+} , also as MRI agents. These studies are undergoing, and future developments will be published elsewhere.

Authors contributions

Mário J.F. Calvete and Sara M.A. Pinto synthesized and characterized the compounds. Sara M.A. Pinto performed the photophysical assessment. Mariette M. Pereira was in article conception, result discussion and writing. Hugh D. Burrows, M. Margarida C.A. Castro and Carlos F. G. C. Geraldês

assisted them in the discussion of the results and writing of the manuscript.

Acknowledgements

The authors thank FCT-Portugal (Portuguese Foundation for Science and Technology) and FEDER – European Regional Development Fund through the COMPETE Programme (Operational Programme for Competitiveness) for funding with PEst-OE/QUI/UI0313/2014, UID/QUI/00313/2013 and PTDC/QEQ-MED/3521/2014. S.M.A.P. and M.J.F.C. are grateful for SFRH/BPD/84619/2012 and SFRH/BPD/99698/2014, respectively.

References

- Adler, A.D., Shergali, W., Longo, F.R., 1964. Mechanistic Investigations of porphyrin syntheses. I. Preliminary studies on Mes-tetraphenylporphyrin. *J. Am. Chem. Soc.* 86, 3145. <https://doi.org/10.1021/Ja01069a035>.
- Arnaut, L.G., 2011. Design of porphyrin-based photosensitizers for photodynamic therapy. *Adv. Inorg. Chem.* 63, 187–233. <https://doi.org/10.1016/B978-0-12-385904-4.00006-8>.
- Blotny, G., 2006. Recent applications of 2,4,6-trichloro-1,3,5-triazine and its derivatives in organic synthesis. *Tetrahedron* 62, 9507–9522. <https://doi.org/10.1016/j.tet.2006.07.039>.
- Calvete, M.J.F., Dias, L.D., Henriques, C.A., Pinto, S.M.A., Carrilho, R.M.B., Pereira, M.M., 2017a. A cost-efficient method for unsymmetrical meso-aryl porphyrin synthesis using NaY zeolite as an inorganic acid catalyst. *Molecules* 22, 741. <https://doi.org/10.3390/Molecules22050741>.
- Calvete, M.J.F., Pinto, S.M., Abrunhosa, A.J., Pereira, M.M., 2017b. Tetrapyrrolic Macrocycles as Molecular Probes for Radionuclide-Based Imaging Techniques. In: Berhardt, L.V. (Ed.), *Advances in Medicine and Biology*. Nova Science Publishers, New York.
- Calvete, M.J.F., Pinto, S.M.A., Pereira, M.M., Geraldes, C.F.G.C., 2017c. Metal coordinated pyrrole-based macrocycles as contrast agents for magnetic resonance imaging technologies: Synthesis and applications. *Coord. Chem. Rev.* 333, 82–107. <https://doi.org/10.1016/j.ccr.2016.11.011>.
- Calvete, M.J.F., Simoes, A.V.C., Henriques, C.A., Pinto, S.M.A., Pereira, M.M., 2014. Tetrapyrrolic macrocycles: potentialities in medical imaging technologies. *Curr. Org. Synth.* 11, 127–140. <https://doi.org/10.2174/15701794113106660090>.
- Cremlyn, R.J., 2002. Sulfonation and chlorosulfonation of aromatic compounds using chlorosulfonic acid. In: *Chlorosulfonic Acid: A Versatile Reagent* Ch. 4. The Royal Society of Chemistry, Cambridge, pp. 35–145.
- Dabrowski, J.M., Arnaut, L.G., Pereira, M.M., Urbanska, K., Simoes, S., Stochel, G., Cortes, L., 2012. Combined effects of singlet oxygen and hydroxyl radical in photodynamic therapy with photostable bacteriochlorins: Evidence from intracellular fluorescence and increased photodynamic efficacy in vitro. *Free Radical. Bio Med.* 52, 1188–1200. <https://doi.org/10.1016/j.freeradbiomed.2011.12.027>.
- Dabrowski, J.M., Krzykawska, M., Arnaut, L.G., Pereira, M.M., Monteiro, C.J.P., Simoes, S., Urbanska, K., Stochel, G., 2011. Tissue uptake study and photodynamic therapy of melanoma-bearing mice with a nontoxic, effective chlorin. *Chemmedchem* 6, 1715–1726. <https://doi.org/10.1002/cmde.201100186>.
- Dong, L.L., Zhang, P., Lei, P.P., Song, S.Y., Xu, X., Du, K.M., Feng, J., Zhang, H.J., 2017. PEGylated GdF₃: Fe nanoparticles as multimodal T-1/T-2-weighted MRI and X-ray CT imaging contrast agents. *ACS Appl. Mater. Inter.* 9, 20426–20434. <https://doi.org/10.1021/acsami.7b04438>.
- Dong, R.N., Qiu, Y., Tian, S.F., Wang, S.Q., Song, X.Q., 1998. Oxidative biomacromolecular damage from novel phthalocyanine. *Sci. China B* 41, 45–49. <https://doi.org/10.1007/Bf02875555>.
- Drechsler, U., Pfaff, M., Hanack, M., 1999. Synthesis of novel functionalised zinc phthalocyanines applicable in photodynamic therapy. *Eur. J. Org. Chem.*, 3441–3453. [https://doi.org/10.1002/\(SICI\)1099-0690\(199912\)1999:12<3441::AID-EJOC3441>3.0.CO;2-Y](https://doi.org/10.1002/(SICI)1099-0690(199912)1999:12<3441::AID-EJOC3441>3.0.CO;2-Y).
- Ethirajan, M., Chen, Y.H., Joshi, P., Pandey, R.K., 2011. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. *Chem. Soc. Rev.* 40, 340–362. <https://doi.org/10.1039/b915149b>.
- Ferreira, M.F., Martins, A.F., Martins, C.I.O., Ferreira, P.M., Toth, E., Rodrigues, T.B., Calle, D., Cerdan, S., Lopez-Larrubia, P., Martins, J.A., Geraldes, C.F.G.C., 2013. Amide conjugates of the DO3A-N-(alpha-amino)propionate ligand: leads for stable, high relaxivity contrast agents for MRI? *Contrast Media Mol. I* 8, 40–49. <https://doi.org/10.1002/cmmi.1492>.
- Ferreira, M.F., Martins, A.F., Martins, J.A., Ferreira, P.M., Toth, E., Geraldes, C.F.G.C., 2009. Gd(DO3A-N-alpha-aminopropionate): a versatile and easily available synthon with optimized water exchange for the synthesis of high relaxivity, targeted MRI contrast agents. *Chem. Commun.*, 6475–6477. <https://doi.org/10.1039/b912201j>.
- Gambhir, S.S., 2002. Molecular imaging of cancer with positron emission tomography. *Nat. Rev. Cancer* 2, 683–693. <https://doi.org/10.1038/nrc882>.
- Gonsalves, A.M.A.R., Varejao, J.M.T.B., Pereira, M.M., 1991. Some new aspects related to the synthesis of mesosubstituted porphyrins. *J. Heterocyclic Chem.* 28, 635–640. <https://doi.org/10.1002/jhet.5570280317>.
- Gonsalves, A.M.D.R., Johnstone, R.A.W., Pereira, M.M., deSantAna, A.M.P., Serra, A.C., Sobral, A.J.F.N., Stocks, P.A., 1996. New procedures for the synthesis and analysis of 5,10,15,20-tetrakis (sulphophenyl)porphyrins and derivatives through chlorosulphonation. *Heterocycles* 43, 829–838. <https://doi.org/10.3987/COM-95-7372>.
- Haywood-Small, S.L., Vernon, D.I., Griffiths, J., Schofield, J., Brown, S.B., 2006. Phthalocyanine-mediated photodynamic therapy induces cell death and a G(0)/G(1) cell cycle arrest in cervical cancer cells. *Biochem. Bioph. Res. Commun.* 339, 569–576. <https://doi.org/10.1016/j.bbrc.2005.11.046>.
- Henriques, C.A., Goncalves, N.P.F., Abreu, A.R., Calvete, M.J.F., Pereira, M.M., 2012. Unsymmetrical porphyrins: the role of meso-substituents on their physical properties. *J. Porphyr. Phthalocya.* 16, 290–296. <https://doi.org/10.1142/S1088424612500332>.
- Henriques, C.A., Pinto, S.M.A., Aquino, G.L.B., Pineiro, M., Calvete, M.J.F., Pereira, M.M., 2014. Ecofriendly porphyrin synthesis by using water under microwave irradiation. *Chemuschem* 7, 2821–2824. <https://doi.org/10.1002/cssc.201402464>.
- Henriques, C.A., Pinto, S.M.A., Canotilho, J., Eusebio, M.E.S., Calvete, M.J.F., 2016. Synthesis of low melting point porphyrins: A quest for new materials. *J. Porphyr. Phthalocya.* 20, 843–854. <https://doi.org/10.1142/S1088424616500516>.
- Henriques, C.A., Pinto, S.M.A., Pineiro, M., Canotilho, J., Eusebio, M.E.S., Pereira, M.M., Calvete, M.J.F., 2015. Solventless metalation of low melting porphyrins synthesized by the water/microwave method. *Rsc Adv.* 5, 64916–64924. <https://doi.org/10.1039/c5ra11820d>.
- Josefsen, L.B., Boyle, R.W., 2012. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. *Theranostics* 2, 916–966. <https://doi.org/10.7150/thno.4571>.
- Kueny-Stotz, M., Garofalo, A., Felder-Flesch, D., 2012. Manganese-enhanced MRI contrast agents: from small chelates to nanosized hybrids. *Eur. J. Inorg. Chem.*, 1987–2005. <https://doi.org/10.1002/ejic.201101163>.

- Lobo, A.C.S., Silva, A.D., Tome, V.A., Pinto, S.M.A., Silva, E.F.F., Calvete, M.J.F., Gomes, C.M.F., Pereira, M.M., Arnaut, L.G., 2016. Phthalocyanine labels for near-infrared fluorescence imaging of solid tumors. *J. Med. Chem.* 59, 4688–4696. <https://doi.org/10.1021/acs.jmedchem.6b00054>.
- Luechai, A., Gasiorowski, J., Petsom, A., Neugebauer, H., Sariciftci, N.S., Thamyongkit, P., 2012. Photosensitizing porphyrin-triazine compound for bulk heterojunction solar cells. *J. Mater. Chem.* 22, 23030–23037. <https://doi.org/10.1039/c2jm33840h>.
- Luo, J., Chen, L.F., Hu, P., Chen, Z.N., 2014. Tetranuclear gadolinium(III) porphyrin complex as a theranostic agent for multimodal imaging and photodynamic therapy. *Inorg. Chem.* 53, 4184–4191. <https://doi.org/10.1021/jc500238s>.
- Marques, A.T., Pinto, S.M.A., Monteiro, C.J.P., de Melo, J.S.S., Burrows, H.D., Scherf, U., Calvete, M.J.F., Pereira, M.M., 2012. Energy transfer from fluorene-based conjugated polyelectrolytes to on-chain and self-assembled porphyrin units. *J. Polym. Sci. Pol. Chem.* 50, 1408–1417. <https://doi.org/10.1002/pola.25908>.
- Martinez-Diaz, M.V., de la Torre, G., Torres, T., 2010. Lighting porphyrins and phthalocyanines for molecular photovoltaics. *Chem. Commun.* 46, 7090–7108. <https://doi.org/10.1039/c0cc02213f>.
- Mewis, R.E., Archibald, S.J., 2010. Biomedical applications of macrocyclic ligand complexes. *Coord. Chem. Rev.* 254, 1686–1712. <https://doi.org/10.1016/j.ccr.2010.02.025>.
- Mikhaleenko, S.A., Solov'eva, L.I., Luk'yanets, E.A., 2004. Phthalocyanines and related compounds: XXXVII. Synthesis of covalent conjugates of carboxy-substituted phthalocyanines with alpha-amino acids. *Russ. J. Gen. Chem.* 74, 451–459. <https://doi.org/10.1023/B:Rugc.0000030404.00492.D1>.
- Monteiro, C.J.P., Pereira, M.M., Pinto, S.M.A., Simoes, A.V.C., Sa, G.F.F., Arnaut, L.G., Formosinho, S.J., Simoes, S., Wyatt, M.F., 2008. Synthesis of amphiphilic sulfonamide halogenated porphyrins: MALDI-TOFMS characterization and evaluation of 1-octanol/water partition coefficients. *Tetrahedron* 64, 5132–5138. <https://doi.org/10.1016/j.tet.2008.03.055>.
- Murov, S.L., Carmichael, I., Hug, G.L., 1993. *Handbook of Photochemistry*. Marcel Dekker, New York.
- Neves, A.C.B., Pinto, S.M.A., Henriques, C.A., Rosado, M.T.S., Mallavia, R., Burrows, H.D., Pereira, M.M., Calvete, M.J.F., 2012. Routes to synthesis of porphyrins covalently bound to poly(carbazole)s and poly(fluorene)s: Structural and computational studies on oligomers. *J. Mol. Struct.* 1029, 199–208. <https://doi.org/10.1016/j.molstruc.2012.06.056>.
- Pan, D., Kim, B., Wang, L.H.V., Lanza, G.M., 2013. A brief account of nanoparticle contrast agents for photoacoustic imaging. *Wires Nanomed. Nanobi.* 5, 517–543. <https://doi.org/10.1002/wnan.1231>.
- Pansare, V.J., Hejazi, S., Faenza, W.J., Prud'homme, R.K., 2012. Review of long-wavelength optical and NIR imaging materials: contrast agents, fluorophores, and multifunctional nano carriers. *Chem. Mater.* 24, 812–827. <https://doi.org/10.1021/cm2028367>.
- Pereira, M.M., Arnaut, L.G., Simoes, S.J.F., Monteiro, C., 2006. Novel Derivatives of Porphyrin, Particularly Chlorins and/or Bacteriochlorins, and Uses Thereof in Photodynamic Therapy. US Patent WO/2006/053707, 26 June 2006.
- Pinto, S.M.A., Henriques, C.A., Tome, V.A., Vinagreiro, C.S., Calvete, M.J.F., Dabrowski, J.M., Pineiro, M., Arnaut, L.G., Pereira, M.M., 2016. Synthesis of meso-substituted porphyrins using sustainable chemical processes. *J. Porphyr. Phthalocya.* 20, 45–60. <https://doi.org/10.1142/S1088424616300020>.
- Pinto, S.M.A., Lourenco, M.A.O., Calvete, M.J.F., Abreu, A.R., Rosado, M.T.S., Burrows, H.D., Pereira, M.M., 2011. Synthesis of new metalloporphyrin triads: efficient and versatile tripod optical sensor for the detection of amines. *Inorg. Chem.* 50, 7916–7918. <https://doi.org/10.1021/jc200727f>.
- Pinto, S.M.A., Neves, A.C.B., Calvete, M.J.F., Abreu, A.R., Rosado, M.T.S., Costa, T., Burrows, H.D., Pereira, M.M., 2012. Metalloporphyrin triads: Synthesis and photochemical characterization. *J. Photoch. Photobio. A* 242, 59–66. <https://doi.org/10.1016/j.jphotochem.2012.05.031>.
- Puthiaraj, P., Lee, Y.R., Zhang, S.Q., Ahn, W.S., 2016. Triazine-based covalent organic polymers: design, synthesis and applications in heterogeneous catalysis. *J. Mater. Chem. A* 4, 16288–16311. <https://doi.org/10.1039/c6ta06089g>.
- Rangacharyulu, C., Roh, C.K., 2015. Isotopes for combined PET/SPECT imaging. *J. Radioanal. Nucl. Ch.* 305, 87–92. <https://doi.org/10.1007/s10967-015-3945-4>.
- Silva, M., Fernandes, A., Bebiano, S.S., Calvete, M.J.F., Ribeiro, M. F., Burrows, H.D., Pereira, M.M., 2014. Size and ability do matter! Influence of acidity and pore size on the synthesis of hindered halogenated meso-phenyl porphyrins catalysed by porous solid oxides. *Chem. Commun.* 50, 6571–6573. <https://doi.org/10.1039/c4cc01100g>.
- Simoes, A.V.C., Adamowicz, A., Dabrowski, J.M., Calvete, M.J.F., Abreu, A.R., Stochel, G., Arnaut, L.G., Pereira, M.M., 2012. Amphiphilic meso(sulfonate ester fluoroaryl)porphyrins: refining the substituents of porphyrin derivatives for phototherapy and diagnostics. *Tetrahedron* 68, 8767–8772. <https://doi.org/10.1016/j.tet.2012.08.007>.
- Simoes, A.V.C., Pinto, S.M.A., Calvete, M.J.F., Gomes, C.M.F., Ferreira, N.C., Castelo-Branco, M., Llop, J., Pereira, M.M., Abrunhosa, A.J., 2015. Synthesis of a new F-18 labeled porphyrin for potential application in positron emission tomography. In vivo imaging and cellular uptake. *Rsc Adv.* 5, 99540–99546. <https://doi.org/10.1039/c5ra16103g>.
- Singh, S., Aggarwal, A., Bhupathiraju, N.V.S.D.K., Arianna, G., Tiwari, K., Drain, C.M., 2015. Glycosylated porphyrins, phthalocyanines, and other porphyrinoids for diagnostics and therapeutics. *Chem. Rev.* 115, 10261–10306. <https://doi.org/10.1021/acs.chemrev.5b00244>.
- Srivatsan, A., Missert, J.R., Upadhyay, S.K., Pandey, R.K., 2015. Porphyrin-based photosensitizers and the corresponding multifunctional nanoplatfoms for cancer-imaging and phototherapy. *J. Porphyr. Phthalocya.* 19, 109–134. <https://doi.org/10.1142/S1088424615300037>.
- Tome, J.P.C., Neves, M.G.P.M.S., Tome, A.C., Cavaleiro, J.A.S., Mendonca, A.F., Pegado, L.S.N., Duarte, R., Valdeira, M.L., 2005. Synthesis of glycoporphyrin derivatives and their antiviral activity against herpes simplex virus types 1 and 2. *Bioorgan. Med. Chem.* 13, 3878–3888. <https://doi.org/10.1016/j.bmc.2005.04.015>.
- Wagnieres, G.A., Star, W.M., Wilson, B.C., 1998. In vivo fluorescence spectroscopy and imaging for oncological applications. *Photochem. Photobiol.* 68, 603–632. <https://doi.org/10.1111/j.1751-1097.1998.tb02521.x>.
- Wu, D., Huang, L., Jiang, M.S., Jiang, H.B., 2014. Contrast agents for photoacoustic and thermoacoustic imaging: a review. *Int. J. Mol. Sci.* 15, 23616–23639. <https://doi.org/10.3390/ijms151223616>.
- Xiao, S.C., Liu, C.Z., Liu, W.K., Xie, W.Z., Lin, W.Y., Jiang, G.F., Guo, C.C., 2010. Selective synthesis and biological activity of triazine-porphyrins as potential anti-cancer agents. *J. Porphyr. Phthalocya.* 14, 123–127. <https://doi.org/10.1142/S1088424610001805>.